Infectious diseases caused by resistant bacteria lead to additional healthcare costs and indirect costs, such as sick-leave and lost output due to premature death. The overall direct costs to society in terms of extra healthcare costs and productivity losses total EUR 1,5 billion each year in Europe [See footnote 2.]; and the indirect costs to European countries are likely to be several times higher [Conference report; Innovative Incentives for Effective Antibacterials (2009).].
Recital 2, Commission Recommendation of 27 October 2011 on the research Joint Programming Initiativ…
In forcesince 27 Oct 2011